XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a bio-pharmaceutical company specializing in the development and commercialization of therapies for progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, and diabetic nephropathy. The company's product portfolio includes XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with COVID-19 and suppress acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidate for the treatment of diabetic nephropathy.

Products

• XRx-008 for autosomal dominant polycystic kidney disease

• XRx-101 for uric acid lowering in COVID-19 patients

• XRx-221 for diabetic nephropathy treatment